Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T17:13:32.343Z.
Consensus retrieved: unavailable. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T17:13:32.343Z.
Quote observation: 2026-10-06T16:57:12.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0a8ac43d83dffe882666147bba78c75a2aa07862642b14baa2694f769a95b4c3
FORWARD PE RATIO
N/A
Lunai Bioworks Inc.
Market Cap
$5.30M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Lunai Bioworks Inc. (LNAI) | $5.30M | N/A |
| Intelligent Bio Solutions Inc. (INBS)vs › | $5.31M | N/A |
| Gelteq Limited Ordinary Shares (GELS)vs › | $5.23M | N/A |
| Alzamend Neuro Inc (ALZN)vs › | $5.23M | N/A |
| Soligenix, Inc. (SNGX)vs › | $5.38M | N/A |
| Pulmatrix, Inc. (PULM)vs › | $5.41M | N/A |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $5.18M | N/A |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN)vs › | $5.16M | N/A |
| Imunon, Inc. (IMNN)vs › | $5.04M | N/A |
| Xenetic Biosciences, Inc. (XBIO)vs › | $5.01M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus fiscal-year EPS
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
